<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
<META NAME="author" CONTENT="Monty Jennings">
<META NAME="date" CONTENT="08/31/2015">
</HEAD>
<BODY style="margin-top:0;font-family:'Times New Roman'; font-size:10pt; color:#000000">
<DIV style="width:624px"><P style="margin:0px; font-size:11.5pt" align=center>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px; font-size:12pt" align=center><B>FORM 8-K</B></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px; font-size:11pt" align=center><B>CURRENT REPORT</B></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px; font-size:11pt" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px; font-size:11pt" align=center>Date of Report (Date of earliest event reported): &nbsp;&nbsp;&nbsp;&nbsp;August 21, 2015</P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px; font-size:14pt" align=center><B><U>VITRO DIAGNOSTICS, INC.<BR>
</U></B><FONT style="font-size:9pt">(Exact Name of Registrant as Specified in its Charter)</FONT></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0 align=center><TR height=0 style="font-size:0"><TD width=227.933 /><TD width=168.067 /><TD width=186 /></TR>
<TR><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=227.933><P style="margin:0px; font-size:11pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nevada&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
</TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=168.067><P style="margin:0px; font-size:11pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0-17378&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
</TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=186><P style="margin:0px; font-size:11pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;84-1012042&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
</TD></TR>
<TR><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=227.933><P style="margin:0px; font-size:9pt">(State or other jurisdiction<BR>
 of incorporation)</P>
</TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=168.067><P style="margin:0px; font-size:9pt">Commission File<BR>
Number</P>
</TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=186><P style="margin:0px; font-size:9pt">(I.R.S. Employer Identification number)</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:11pt" align=center><U>4621 Technology Drive, Golden CO &nbsp;80403<BR>
</U><FONT style="font-size:9pt">(Address of principal executive offices)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Zip Code)</FONT></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px; font-size:11pt" align=center>Registrant's telephone number, including area code:&nbsp;&nbsp;&nbsp;<U>(303) 999-2130</U></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px; font-size:9pt" align=center>______________________________________________________</P>
<P style="margin:0px; font-size:9pt" align=center>(Former name or former address, if changed since last report)</P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px"><BR></P>
</DIV><TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=55.2 /><TD width=583.2 /></TR>
<TR><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=55.2><P style="margin:0px; font-size:11.5pt">___</P>
</TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=583.2><P style="margin:0px; font-size:11.5pt">Written communications pursuant to Rule 425 under the Securities Act </P>
</TD></TR>
<TR><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=55.2><P style="margin:0px; font-size:11.5pt">___</P>
</TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=583.2><P style="margin:0px; font-size:11.5pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act</P>
</TD></TR>
<TR><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=55.2><P style="margin:0px; font-size:11.5pt">___</P>
</TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=583.2><P style="margin:0px; font-size:11.5pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act</P>
</TD></TR>
<TR><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=55.2><P style="margin:0px; font-size:11.5pt">___</P>
</TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=583.2><P style="margin:0px; font-size:11.5pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act</P>
</TD></TR>
</TABLE>
<DIV style="width:624px"><P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<HR style="margin-bottom:9.6px; padding-top:9.6px" noshade size=1.333>
<P style="margin:0px; page-break-before:always"><BR></P>
</DIV><TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=121.2 /><TD width=543.867 /></TR>
<TR><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=121.2><P style="margin:0px; font-size:11.5pt"><B><U>ITEM 3.02</U></B></P>
</TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=543.867><P style="margin:0px; font-size:11.5pt"><B><U>UNREGISTERED SALE OF EQUITY SECURITIES</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=121.2><P style="margin:0px; padding-left:9.6px; padding-right:9.6px; font-size:11.5pt">&nbsp;</P></TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=543.867><P style="margin:0px; padding-left:9.6px; padding-right:9.6px; font-size:11.5pt">&nbsp;</P></TD></TR>
<TR><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=121.2><P style="margin:0px; font-size:11.5pt"><B><U>ITEM 8.01</U></B></P>
</TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=543.867><P style="margin:0px; font-size:11.5pt"><B><U>OTHER EVENTS</U></B></P>
</TD></TR>
</TABLE>
<DIV style="width:624px"><P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; text-indent:48px; font-size:12pt" align=justify>On August 21, 2015, &nbsp;Vitro Diagnostics, Inc. (the &#147;Company&#148;) entered into an agreement (the &#147;Agreement&#148;) with C. Brook Ventures, Inc. (&#147;CBV&#148;) pursuant to which CBV will provide non-exclusive advisory services related to the Company&#146;s exploration of strategic alternatives to enhance stockholder value.</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; text-indent:48px; font-size:12pt" align=justify>Under the terms of the Agreement, the Company agreed to pay CBV a retainer of $5,000 and issue to CBV an aggregate of 400,000 shares of common stock, $.001 par value. &nbsp;The shares are &#147;restricted securities&#148; under the Securities Act of 1933, as amended.</P>
<P style="margin:0px" align=justify><BR></P>
<P style="margin:0px; text-indent:48px; font-size:12pt" align=justify>In addition, the Agreement provides that the Company will grant and issue to CBV a warrant (&#147;Warrant&#148;) exercisable for three years to purchase an additional 400,000 shares at an exercise price of $0.078936 (120% of the 20 day VWAP immediately preceding the execution of the Agreement.) &nbsp;The Warrant is only exercisable if the Company consummates a transaction identified in the Agreement with a third party introduced by CBV prior to the expiration date of the Warrant.</P>
<P style="margin:0px"><BR></P>
</DIV><TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=121.2 /><TD width=543.867 /></TR>
<TR><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=121.2><P style="margin:0px; font-size:11.5pt"><B><U>ITEM 9.01</U></B></P>
</TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=543.867><P style="margin:0px; font-size:12pt"><B><U>EXHIBITS</U></B></P>
</TD></TR>
</TABLE>
<DIV style="width:624px"><P style="margin:0px"><BR></P>
<P style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:96px; font-size:12pt; float:left">10.1</P>
<P style="margin:0px; text-indent:-2px; font-size:12pt">Agreement with C. Brook Ventures, Inc. dated August 21, 2015</P>
<P style="margin:0px; clear:left"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:11.5pt" align=center><B>SIGNATURES</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; text-indent:48px; font-size:11.5pt" align=justify>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>
<P style="margin:0px"><BR></P>
</DIV><TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:0"><TD width=43.2 /><TD width=276 /><TD width=18 /><TD width=301.2 /></TR>
<TR><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=43.2><P style="margin:0px">&nbsp;</P></TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=276><P style="margin:0px">&nbsp;</P></TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=319.2 colspan=2><P style="margin:0px; font-size:11.5pt"><B>Vitro Diagnostics, Inc. <BR>
</B>(Registrant)</P>
</TD></TR>
<TR><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=43.2><P style="margin:0px; padding-left:9.6px; padding-right:9.6px; font-size:11.5pt">&nbsp;</P></TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=276><P style="margin:0px; padding-left:9.6px; padding-right:9.6px; font-size:11.5pt">&nbsp;</P></TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=18><P style="margin:0px; padding-left:9.6px; padding-right:9.6px; font-size:11.5pt">&nbsp;</P></TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=301.2><P style="margin:0px; padding-left:9.6px; padding-right:9.6px; font-size:11.5pt">&nbsp;</P></TD></TR>
<TR><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=43.2><P style="margin:0px; padding-left:9.6px; padding-right:9.6px; font-size:11.5pt">&nbsp;</P></TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=276><P style="margin:0px; font-size:11.5pt">Dated:<U>&nbsp;August 27, 2015</U></P>
</TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=18><P style="margin:0px; padding-left:9.6px; padding-right:9.6px; font-size:11.5pt">&nbsp;</P></TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=301.2><P style="margin:0px; font-size:11.5pt"><U>__</U><I>/s/<U>James R. Musick</U></I></P>
<P style="margin:0px; font-size:11.5pt">James R. Musick, President</P>
<P style="margin:0px; font-size:11.5pt">and Chief Executive Officer</P>
</TD></TR>
<TR><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=43.2><P style="margin:0px; padding-left:9.6px; padding-right:9.6px; font-size:11.5pt">&nbsp;</P></TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=276><P style="margin:0px; padding-left:9.6px; padding-right:9.6px; font-size:11.5pt">&nbsp;</P></TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=18><P style="margin:0px; padding-left:9.6px; padding-right:9.6px; font-size:11.5pt">&nbsp;</P></TD><TD style="margin-top:0px; padding-left:9.6px; padding-top:0px; padding-right:9.6px; padding-bottom:0px" valign=top width=301.2><P style="margin:0px; padding-left:9.6px; padding-right:9.6px; font-size:11.5pt">&nbsp;</P></TD></TR>
</TABLE>
<DIV style="width:624px"><P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px" align=center>2</P>
<P style="margin:0px"><BR></P>
</DIV></BODY>
<!-- EDGAR Validation Code: 2FC27A9C -->
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "vds_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 14422}]
{"company-data": {"conformed-name": "VITRO DIAGNOSTICS INC", "cik": "0000793171", "assigned-sic": "2836", "irs-number": "841012042", "state-of-incorporation": "NV", "fiscal-year-end": "1031"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-17378", "film-number": "151085767"}, "business-address": {"street1": "4621 TECHNOLOGY DRIVE", "city": "GOLDEN", "state": "CO", "zip": "80403", "phone": "(720) 859-4120"}, "mail-address": {"street1": "4621 TECHNOLOGY DRIVE", "city": "GOLDEN", "state": "CO", "zip": "80403"}, "former-company": [{"former-conformed-name": "LABTEK INC", "date-changed": "19870217"}, {"former-conformed-name": "IMPERIAL MANAGEMENT INC", "date-changed": "19870201"}]}
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):     August 21, 2015
VITRO DIAGNOSTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Nevada
0-17378
84-1012042
(State or other jurisdiction
of incorporation)
Commission File
Number
(I.R.S. Employer Identification number)
4621 Technology Drive, Golden CO  80403
(Address of principal executive offices)                    (Zip Code)
Registrant's telephone number, including area code:
(303) 999-2130
______________________________________________________
(Former name or former address, if changed since last report)
___
Written communications pursuant to Rule 425 under the Securities Act
___
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
___
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
___
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
ITEM 3.02
UNREGISTERED SALE OF EQUITY SECURITIES
ITEM 8.01
OTHER EVENTS
On August 21, 2015,  Vitro Diagnostics, Inc. (the "Company") entered into an agreement (the "Agreement") with C. Brook Ventures, Inc. ("CBV") pursuant to which CBV will provide non-exclusive advisory services related to the Company's exploration of strategic alternatives to enhance stockholder value.
Under the terms of the Agreement, the Company agreed to pay CBV a retainer of $5,000 and issue to CBV an aggregate of 400,000 shares of common stock, $.001 par value.  The shares are "restricted securities" under the Securities Act of 1933, as amended.
In addition, the Agreement provides that the Company will grant and issue to CBV a warrant ("Warrant") exercisable for three years to purchase an additional 400,000 shares at an exercise price of $0.078936 (120% of the 20 day VWAP immediately preceding the execution of the Agreement.)  The Warrant is only exercisable if the Company consummates a transaction identified in the Agreement with a third party introduced by CBV prior to the expiration date of the Warrant.
ITEM 9.01
EXHIBITS
10.1
Agreement with C. Brook Ventures, Inc. dated August 21, 2015
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Vitro Diagnostics, Inc.
(Registrant)
Dated:
August 27, 2015
__
/s/
James R. Musick
James R. Musick, President
and Chief Executive Officer
2